Otsuka Pharmaceutical's Voyxact (sibeprenlimab-szsi) stabilised kidney function for over two years in patients with primary IgA nephropathy (IgAN) at risk for disease progression.
Barchart on MSN
Nasdaq futures climb as tech rally continues on Palantir boost, US JOLTS report and SpaceX earnings on tap
September Nasdaq 100 E-Mini futures (NQU26) are up +0.67% this morning, signaling further gains for tech stocks as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results